Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.
Citizens analyst Daniel Stauder maintains AtriCure (NASDAQ:ATRC) with a Market Outperform and raises the price target from $52 to $68.